Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
School of Baccalaureate Nursing, St. Lawrence College, Kingston, ON, Canada.
Methods Mol Biol. 2023;2663:111-125. doi: 10.1007/978-1-0716-3175-1_7.
Normal pregnancy is associated with significant physiological changes in the coagulation and fibrinolytic systems with an inclination toward a hypercoagulable state. This includes an increase in plasma levels of most clotting factors, a decrease in endogenous anticoagulants, and inhibition of fibrinolysis. Although these changes are critical in maintaining placental function and reducing postpartum hemorrhage, they may contribute to an increased risk of thromboembolism, particularly toward the end of pregnancy and during puerperium. Hemostasis parameters and the non-pregnant population reference ranges cannot be used in the assessment of bleeding or thrombotic complication risk during pregnancy, and pregnancy-specific information and reference ranges are not always available to support the interpretation of laboratory tests. This review aims to summarize the use of relevant hemostasis tests to promote evidence-based interpretation of laboratory test results as well as discuss challenges associated with testing during pregnancy.
正常妊娠伴随着凝血和纤维蛋白溶解系统的显著生理变化，倾向于高凝状态。这包括大多数凝血因子的血浆水平增加、内源性抗凝剂减少和纤维蛋白溶解抑制。虽然这些变化对于维持胎盘功能和减少产后出血至关重要，但它们可能导致血栓栓塞的风险增加，特别是在妊娠末期和产褥期。止血参数和非妊娠人群的参考范围不能用于评估妊娠期间出血或血栓并发症的风险，并且并非总是有妊娠特异性信息和参考范围来支持实验室检测的解读。本文旨在总结相关止血检测的应用，以促进基于证据的实验室检测结果解读，并讨论与妊娠期间检测相关的挑战。
